Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM7 | Q14831 | 3/20 | 0.43 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.42 |
| ▸ | MTNR1A | P48039 | 6/20 | 0.41 |
| ▸ | MTNR1B | P49286 | 6/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.38 |
| ▸ | FABP5 | Q01469 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3320680 | 0.89 | MTNR1A (0.54) | HRH3MTNR1AMTNR1BCA1CA2 | |
| SCHEMBL6589968 | 0.77 | CA1 (0.52) | GRM7MTNR1AMTNR1BMAPTCA1 | |
| SCHEMBL3315944 | 0.76 | TAS1R3 (0.36) | GRM7HRH3MTNR1AMTNR1B | |
| SCHEMBL3316278 | 0.75 | MAOA (0.49) | CA1CA2 | |
| SCHEMBL3313789 | 0.74 | FAAH (0.46) | GRM7LMNARAB9A | |
| SCHEMBL3317018 | 0.74 | HTR1D (0.52) | MTNR1AMTNR1BCA1CA2 | |
| SCHEMBL3320952 | 0.73 | HTT (0.56) | LMNA | |
| SCHEMBL19280183 | 0.73 | THRB (0.34) | — | |
| SCHEMBL4696472 | 0.71 | ALDH1A1 (0.49) | HRH3GRIN2BLMNA | |
| SCHEMBL433595 | 0.71 | GRIN2B (0.52) | MTNR1AMTNR1BCA1CA2GRIN2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100105651-A1 | ANTAGONISTS OF SNS SODIUM CHANNELS | VERNALIS (R&D) LIMITED (GB) | 2010-04-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100105651-A1 | ANTAGONISTS OF SNS SODIUM CHANNELS | CNR1, OPRL1, CHRNA10 | GRM7 487/4885HRH3 360/4885MTNR1A 42/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.